Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Vangl1 peptides and vaccines including the same

An immunology and antigen technology, applied in the field of drugs for the treatment and prevention of tumors, can solve problems such as low objective response rate

Inactive Publication Date: 2012-05-02
ONCOTHERAPY SCI INC
View PDF26 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Unfortunately, only low objective response rates have been observed so far in these cancer vaccine trials (NPL 11 / Belli F et al., J Clin Oncol 2002 Oct 15, 20(20):4169-80; NPL 12 / Coulie PG et al., Immunol Rev 2002 Oct, 188:33-42; NPL 13 / Rosenberg SA et al., Nat Med 2004 Sep, 10(9):909-15)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Vangl1 peptides and vaccines including the same
  • Vangl1 peptides and vaccines including the same
  • Vangl1 peptides and vaccines including the same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0352] Materials and methods

[0353] cell line

[0354] The A24 lymphoblastoid cell line (A24LCL) was established by transforming Epstein-bar virus into HLA-A24 positive human B lymphocytes. COS7, an African green monkey kidney cell line, was purchased from ATCC.

[0355] Selection of candidates for VANGL1-derived peptides

[0356] Using the binding prediction software "BIMAS" (www-bimas.cit.nih.gov / molbio / hla_bind) (Parker et al. (J Immunol 1994, 152(1): 163-75), Kuzushima et al. (Blood 2001, 98(6):1872-81))) predicts VANGL1-derived 9-mer and 10-mer peptides that bind HLA-A*2402 molecules. The peptides were synthesized by SIGMA (Sapporo, Japan) following standard solid phase synthesis and purified by reverse phase high performance liquid chromatography (HPLC). The purity (>90%) and identity of the peptides were determined by analytical HPLC and mass spectrometry analysis, respectively. Peptides were dissolved in dimethyl sulfoxide (DMSO) at 20 mg / ml and stored at -8...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides isolated peptides or the fragments derived from SEQ ID NO: 35, which bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL). The peptides may include one of the above mentioned amino acid sequences with substitution, deletion, or addition of one, two, or several amino acids sequences. The present invention also provides pharmaceutical compositions including these peptides. The peptides of this invention can be used for treating cancer.

Description

technical field [0001] This application claims the benefit of US Provisional Application No. 61 / 209,242, filed March 4, 2009, the entire contents of which are hereby incorporated by reference. [0002] The present invention relates to the field of biological sciences, more specifically to the field of cancer treatment. Specifically, the present invention relates to novel peptides which are extremely effective as cancer vaccines and drugs for treating and preventing tumors. Background technique [0003] It has been demonstrated that CD8-positive CTLs can recognize epitope peptides derived from tumor-associated antigens (TAAs) on major histocompatibility complex (MHC) class I molecules, and then kill tumor cells. Since the discovery of the first example of TAA - the melanoma antigen (MAGE) family, people have used immunological means (NPL1 / Boon T, Int J Cancer 1993 May 8, 54(2): 177-80; NPL 2 / Boon T & van der Bruggen P, J Exp Med 1996 Mar 1, 183(3):725-9) Many other TAAs ha...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N15/09A61K39/00A61K48/00A61P35/00C07K7/06C07K14/705C07K16/30C12N1/15C12N1/19C12N1/21C12N5/07C12N5/10
CPCA61K39/00C07K14/4748A61P35/00A61P37/04A61P43/00C12N5/0634C12N5/0638C07K16/18G01N33/574C12N2501/998G01N2333/47
Inventor 角田卓也大泽龙司吉村祥子渡边朝久
Owner ONCOTHERAPY SCI INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com